What is Molecular Partners AG (MLLCF) stock price today?

Molecular Partners AG (MLLCF) is currently trading at $3.80, up 0% today.

What is MLLCF P/E ratio?

Molecular Partners AG's P/E ratio is -2.13. A negative P/E means the company reported a net loss over the last twelve months, so P/E is not a meaningful valuation measure for it right now.

What is MLLCF return on equity (ROE)?

Molecular Partners AG's return on equity (ROE) is -66.19%. ROE measures net income relative to shareholders' equity. A negative ROE means the company reported a net loss over the period.

What is Molecular Partners AG's market cap?

Molecular Partners AG has a market capitalization of $142.54M.

OTC · Biotechnology

Molecular Partners AG (MLLCF) Stock

$3.80 +0.00% OTC: MLLCF Healthcare

Valuation

Metric	Value
Price	$3.80
Market Cap	$142.54M
P/E Ratio	-2.13
P/B Ratio	1.82
P/S Ratio	0.00
EPS (TTM)	$-1.65
52-Week High	$4.85
52-Week Low	$2.25
Dividend Yield	—

Financials & Margins

Metric	Value
ROE	-66.19%
ROA	-66.25%
ROCE	-70.20%
Gross Margin	0.00%
Operating Margin	0.00%
Net Margin	0.00%
Debt/Equity	0.05
Current Ratio	9.42

Annual Financials (USD)

Metric	2021	2022	2023	2024	2025
Revenue	$9.0M	$190.0M	$7.0M	$5.0M	$0
Operating Profit	$-63.0M	$117.0M	$-61.0M	$-61.0M	$-55.0M
Net Profit	$-64.0M	$118.0M	$-62.0M	$-54.0M	$-62.0M
EPS	$-2.06	$3.54	$-1.89	$-1.63	$-1.65
Op Margin	-679.7%	61.5%	-868.3%	-1231.7%	—

Balance Sheet (USD)

Metric	2021	2022	2023	2024	2025
Total Assets	$173.0M	$262.0M	$198.0M	$159.0M	$102.0M
Total Liabilities	$65.0M	$27.0M	$22.0M	$17.0M	$22.0M
Cash	$72.0M	$88.0M	$67.0M	$64.0M	$93.0M
Borrowings	$6.0M	$5.0M	$4.0M	$2.0M	$4.0M

Latest News

Molecular Partners Doses First Patients in Phase 2 Study of Biliary Tract Cancer Therapy MT Newswires · Jul 16, 2026 Molecular Partners Announces Clinical Progress in Phase 2 TACTIC Combination Trial of MP0317 for Patients with Cholangiocarcinoma GlobeNewswire · Jul 16, 2026 Molecular Partners Showcases Bispecific Radio-DARPins at Gordon Research Conference GlobeNewswire · Jul 15, 2026 Molecular Partners Makes Progress on Radiotherapy Cancer Candidates MT Newswires · Jul 6, 2026 Molecular Partners Updates on Clinical Progress Across Expanding Pipeline of DARPin Radiotherapeutics GlobeNewswire · Jul 6, 2026

Cash Flow (USD)

Metric	2021	2022	2023	2024	2025
Operating Cash Flow	$-91.0M	$119.0M	$-59.0M	$-59.0M	$-50.0M
Investing Cash Flow	$-24.0M	$-103.0M	$44.0M	$40.0M	$70.0M
Financing Cash Flow	$0	$0	$0	$-2.0M	$0
Net Cash Flow	$-62.0M	$16.0M	$-21.0M	$-3.0M	$-37.0M
Free Cash Flow	$-92.0M	$117.0M	$-60.0M	$-60.0M	$-50.0M

Valuation & Return Ratios

Metric	Value
PEG Ratio	—
EV / EBITDA	—
FCF Yield	-35.08%
Quick Ratio	9.42
Interest Coverage	-13.75
Return 1Y	—
Return 3Y	—
Return 5Y	—

Ownership

Insiders Held8.47%

Institutions Held44.06%

Institutions Float Held48.14%

Institutional Holder	Shares	Report Date
Old Mission Capital, LLC	11,347	2025-06-30

Peer Comparison

Ticker	Price	Change	P/E	Market Cap	Div Yield
AAWHAscend Wellness Holdings, Inc.	$0.39	-4.77%	-0.60	$78.17M	0.00%
BRIBFBrii Biosciences Limited	$0.13	+0.00%	-2.71	$90.69M	0.00%
BXPHFBotanix Pharmaceuticals Limited	$0.02	-30.23%	-0.41	$29.89M	0.00%
HOFBFHofseth BioCare ASA	$0.17	+0.00%	-3.90	$68.47M	0.00%
IPHYFInnate Pharma S.A.	$1.65	+0.00%	-2.84	$154.94M	0.00%

About Molecular Partners AG

Molecular Partners AG, a clinical-stage biotechnology company, designs and develops designed ankyrin repeat proteins therapeutics for the treatment of oncology diseases in Switzerland. Its product pipeline comprises MP0317, which is in Phase 2 clinical trial for the treatment of advanced solid tumors; MP053, novel tetra-specific T cell-engaging DARPin, which is phase 1 clinical trial for the treatment of acute myeloid leukemia; and MP0712, a 212Pb Radio-DARPin therapy (RDT) candidate targeting the tumor-associated protein delta-like ligand 3 (DLL3) which is in Phase 1 clinical trial to treat SCLC and neuroendocrine tumors. It also researches for Switch-DARPin T cell engager to treat CD3 x costim x; and MP0726, a Radio-DARPin Therapy to treat ovarian cancer and other MSLNexpressing cancers. In addition, the company develops MP0621, a Switch-DARPin candidate targeting CD16a, c-KIT, and CD47 as conditioning for hematopoietic stem cell transplantation; and Radio-DARPin Therapy (RDT) platform, a delivery system for effective and selective delivery of radioactive payloads to solid tumors. It has collaboration agreement with Orano Med SAS to develop novel Radio-DARPin therapeutics and an additional six targeted alpha therapeutics candidates and Eckert & Ziegler SE to develop Radio-DARPin therapeutics. Molecular Partners AG was incorporated in 2004 and is headquartered in Schlieren, Switzerland.

Molecular Partners AG is headquartered in CH.

Molecular Partners AG (MLLCF) stock trades at $3.80 with a market capitalization of $142.54M. The stock is valued at a negative price-to-earnings (P/E) ratio of -2.13, reflecting a net loss over the last twelve months, price-to-book of 1.82, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $2.25 and $4.85, and currently trades 21.6% below its 52-week high.

On profitability, Molecular Partners AG generates a return on equity (ROE) of -66.19% (negative, reflecting a net loss), return on capital employed of -70.20%.

Official website: www.molecularpartners.com